行情

CLVS

CLVS

Clovis肿瘤药物
NASDAQ

实时行情|Nasdaq Last Sale

11.72
-0.38
-3.14%
盘后: 11.60 -0.12 -1.02% 19:59 12/11 EST
开盘
12.21
昨收
12.10
最高
12.40
最低
10.85
成交量
991.37万
成交额
--
52周最高
32.05
52周最低
2.930
市值
6.42亿
市盈率(TTM)
-1.5612
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLVS 新闻

  • Waiting On PARP Traction For Clovis; Competition A Concern
  • Seeking Alpha - Article.1天前
  • Clovis Oncology Option Alert: Dec 20 $12 Puts at the Bid: 4000 @ $1.15 vs 6115 OI; Ref=$12.39
  • Benzinga.1天前
  • Implied Volatility Surging for Clovis (CLVS) Stock Options
  • Zacks.1天前
  • Clovis Oncology Option Alert: Apr 17 $8 Puts at the Bid: 1600 @ $2.25 vs 3998 OI; Ref=$10.3913
  • Benzinga.2天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CLVS 简况

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
展开

Webull提供Clovis Oncology Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。